Tesamorelin Injections

Vial Size

Please choose

Product Details

Tesamorelin – Overview

Category: Growth Hormone–Releasing Hormone (GHRH) analog
Administration: Subcutaneous injection, typically daily at bedtime
Primary Use (FDA): Reduce excess abdominal (visceral) fat in HIV-associated lipodystrophy
Off-label Uses: Fat loss (especially visceral fat), anti-aging, muscle preservation, metabolic health, GH/IGF-1 optimization

Mechanism of Action

Tesamorelin mimics GHRH → stimulates the pituitary gland to release more growth hormone (GH).
Increased GH leads to higher insulin-like growth factor 1 (IGF-1) → promotes fat breakdown, muscle preservation, and improved metabolic profile.
Selectively reduces visceral adipose tissue (VAT) without significantly affecting subcutaneous fat.

Expected Benefits

3–6 Months of Consistent Use May Lead To:

Reduction in abdominal/visceral fat (up to 15–20% in clinical studies over 6 months)
Improved body composition and waist circumference
Better workout recovery and muscle tone
Possible improvements in triglycerides and insulin sensitivity
Enhanced sleep quality and energy

Timeline for Results

Weeks 1–2: Increased energy, better sleep, faster recovery
Weeks 3–6: Elevated IGF-1 on labs, mild fat loss
Months 3–6: Noticeable reduction in abdominal fat, improved body composition
6+ months: Sustained fat loss and metabolic benefits with continued use; regain possible if discontinued

Potential Side Effects

Mild injection site redness/itching
Temporary fluid retention or bloating
Joint stiffness, tingling in hands/feet (carpal tunnel–like symptoms)
Headache or mild nausea
Rare: Worsening of pre-existing cancers due to GH/IGF-1 stimulation — screen high-risk patients first

Monitoring

Baseline: CMP, fasting glucose/A1c, IGF-1, lipid panel
Follow-up labs at 6–12 weeks, then every 3–6 months
Watch for symptoms of carpal tunnel, swelling, headaches, or excessive fatigue

Contraindications

Active malignancy
Pregnancy or breastfeeding
Known hypersensitivity to tesamorelin or mannitol
Caution in patients with poorly controlled diabetes, recent MI, or acute critical illness

Tesamorelin Injections